Cognetivity Neurosciences

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Cognetivity Neurosciences had revenue of €31.4k and net profit of -€5.14m

(EUR)	2023	YoY
Revenue	31.4k	-
Gross profit	-1.47m	8,479.92%
Net profit	-5.14m	44.04%
EBITDA	-4.42m	51.54%

Fundamentals

Metric	Value
Market capitalization	€8.03k
Number of shares	89.59m
52-week high/low	€0.0017 - €0.0000897
Dividends	No
Beta	0.74
P/E ratio	-0.12
PEG ratio	-0.01
P/B ratio	-0.10
P/S ratio	19.75

Company profile

Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that helps to detect the earliest signs of impairment by testing the performance of large areas of the brain to support the diagnosis of dementia; and offers OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.